Chemoimmunotherapy Ups PFS in Early-Stage Follicular Lymphoma
TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus.
The ‘CALM’ Approach to Relieving and Preventing Depression in Advanced Cancer
Three and 6 months after undergoing the psychotherapeutic intervention Managing Cancer and Living Meaningfully (CALM), participants reported less-severe depressive symptoms.
What Prompts Male Teens With Cancer to Bank Their Sperm?
A team from Children’s Healthcare of Atlanta reports unexpected factors determining which adolescents participated in sperm banking.
Can Elderly Patients With DLBCL Tolerate Standard Treatment?
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
More Cancer Survivors Have Metabolic Syndrome, but Knowledge and Awareness Vary Widely
While over half of survivors had heard of metabolic syndrome, in one-third with the condition, fewer than 10% had been diagnosed; educational strategies may be of benefit.
Men Less Likely to Prefer Palliative Care Treatment at End of Life
A small study has found that men with cancer were less likely than women to prefer palliative care if informed that continued treatment would not be helpful.
Western Diet Linked With CLL
Findings from the MCC-Spain study suggest that in some cases, CLL could be prevented by modifying dietary habits.
Time to Next FCR Treatment May Predict Poor Prognosis in CLL
Most CLL patients treated with FCR will experience long-term remissions, but patients who relapse within 24 months have a dismal prognosis.
Culprit in Regorafenib Combo Failure in Metastatic Colorectal Cancer?
A 13% absolute increase in the radiographic response rate occurred in regorafenib-treated patients. Survival increases were not statistically significant.
Pooled Data Analysis: Vitamin D Protects Against Colorectal Cancer
For each 25 nmol/L increment of circulating vitamin D, colorectal cancer risk was 19% lower in women and 7% lower in men.
Ibrutinib Monotherapy Not Recommended for R/R FL
In the DAWN trial, however, investigators said, “some patients experienced prolonged remission durations and symptom relief with no new safety signals.”
Prolonged PFS With Obinutuzumab in Advanced FL, Regardless of Chemo Backbone
AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.
Study IDs Common RCC Subtype in Peds, Young Adults
This is the first diagnostic classification of RCCs in patients younger than age 30 prospectively registered in a cooperative group clinical study.
Venetoclax Effective Against CLL in ‘Real-World’ Setting
Overall response was strong even in high-risk patients (over age 65, with 17p deletion, with prior ibrutinib therapy, and mutations of BTK and PLCγ2).
Venetoclax/Rituximab Combo Approved for CLL/SLL
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction.
Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT.
No OS Benefit From PROSTVAC-V/F in mCRPC
OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.
BCMA-Targeting CAR T-Cell Tx Effective in R/R MM
CAR T-cell therapy with bb2121 induced deep, long-lasting responses in patients with heavily pretreated MM.
Adjuvant FOLFOX Improved DFS in yp Stage III Rectal Cancer
In the ADORE trial, adjuvant FOLFOX in postoperative yp stage III rectal cancer significantly improved disease-free survival.
AR-V7+ CTCs Predicted Worse PFS, OS in mCRPC
In the PROPHECY study, men with mCRPC and AR-V7–positive CTCs had only a 0% to 11% probability of benefit from abiraterone or enzalutamide.
No Survival Bump With More Frequent PSA Screens for Localized Prostate Cancer
In AFT-30, increased frequency of PSA screening for localized prostate cancer did not boost survival, regardless of primary treatment or disease risk.
Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.
Abiraterone May Be More Effective in Black Men With Prostate Cancer
In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.
Lynch Syndrome Common in MSI-High Tumors
The presence of MSI-high was predictive of Lynch syndrome, which was found to be associated with a much wider spectrum of cancers than previously thought.
mCRC Chemo Cost More in US Than in Canada, but Yielded No Better Survival
Despite paying nearly double per month for first-line treatment in the US, patients with mCRC have survival outcomes similar to their Canadian counterparts.
Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.
Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.
Prostate Cancer OS Similar for Black vs White Men
A pooled analysis including data from over 8,000 men showed survival outcomes were better for black men, after adjusting for prognostic variables.
Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.
Auto HCT and Matched Sibling Transplant Effective in FL
While HCT is an important benefit for FL patients, the optimal approach remains up for debate.